Connection
Christina Aquilante to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Christina Aquilante has written about Diabetes Mellitus, Type 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.410 |
|
|
|
-
Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):359-72.
Score: 0.136
-
Aquilante CL, Zhang W, McCollum M. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes. Curr Med Res Opin. 2007 Mar; 23(3):489-94.
Score: 0.111
-
Leonard CE, Brensinger CM, Dawwas GK, Deo R, Bilker WB, Soprano SE, Dhopeshwarkar N, Flory JH, Bloomgarden ZT, Gagne JJ, Aquilante CL, Kimmel SE, Hennessy S. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. Cardiovasc Diabetol. 2020 02 25; 19(1):25.
Score: 0.068
-
Bzowyckyj AS, Aquilante CL, Cheng AL, Drees B. Leveraging the Electronic Medical Record to Identify Predictors of Nonattendance to a Diabetes Self-Management Education and Support Program. Diabetes Educ. 2019 10; 45(5):544-552.
Score: 0.066
-
Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics. 2007 Aug; 8(8):917-31.
Score: 0.029